SCM
KDNY

Suvretta Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Suvretta Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,748,141
Closed -$67.2M – 108
2023
Q2 		$67.2M Buy
1,748,141
+179,344
+11% +$4.61M 3.59% 8
2023
Q1 		$36.3M Buy
1,568,797
+123,967
+9% +$2.96M 1.53% 25
2022
Q4 		$37.9M Buy
1,444,830
+54,830
+4% +$1.21M 1.59% 27
2022
Q3 		$27.3M Sell
1,390,000
-394,200
-22% -$7.91M 1.13% 36
2022
Q2 		$31.2M Buy
1,784,200
+350,000
+24% +$5.49M 1.19% 34
2022
Q1 		$23.5M Buy
1,434,200
+186,732
+15% +$2.54M 0.72% 44
2021
Q4 		$20.3M Buy
1,247,468
+200,000
+19% +$2.85M 0.39% 51
2021
Q3 		$13.4M Buy
1,047,468
+79,445
+8% +$1.05M 0.23% 57
2021
Q2 		$13.7M Buy
968,023
+418,408
+76% +$6.69M 0.2% 73
2021
Q1 		$8.54M Buy
549,615
+23,160
+4% +$378K 0.13% 77
2020
Q4 		$8.35M Buy
526,455
+298,199
+131% +$4.5M 0.12% 65
2020
Q3 		$2.77M Buy
228,256
+67,676
+42% +$907K 0.05% 75
2020
Q2 		$1.85M Buy
+160,580
New +$2.21M 0.04% 74

Suvretta Capital Management's KDNY Position: Q3 2023 in Review

Suvretta Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,748,141 shares — an estimated $67.2M sold.

Suvretta Capital Management first reported a position in KDNY in Q2 2020 and held it in 13 quarters. The position peaked at $67.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Suvretta Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Suvretta Capital Management sold 1,748,141 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $67.2M.
  • Suvretta Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2020 and held it in 13 quarters.
  • Suvretta Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $67.2M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Suvretta Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.